Research programme: estradiol dehydrogenase inhibitors - Forendo Pharma
Alternative Names: 17-beta hydroxysteroid dehydrogenase inhibitors; 17-β HSD type-1 inhibitors; 17β-HSD1 inhibitors; Dual HSD inhibitors; Estradiol dehydrogenase inhibitors; HSD inhibitors programme; HSD programme; HSD-1; HSD17B1 inhibitorLatest Information Update: 20 Dec 2021
At a glance
- Originator Hormos Medical; Solvay Pharmaceuticals; University of Turku
- Developer Abbott Laboratories; QuatRx Pharmaceuticals
- Class
- Mechanism of Action Estradiol dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Endometriosis; Uterine leiomyoma